ArticleInternational journal of retina and vitreous2026
Intracameral antibiotic prophylaxis and surgical expertise: key determinants in endophthalmitis after cataract surgery.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative endophthalmitis is a rare but severe complication of cataract surgery. Intracameral moxifloxacin prophylaxis has been widely adopted, but concerns remain regarding bacterial resistance and clinical outcomes. This study aimed to evaluate the impact of intracameral moxifloxacin prophylaxis on endophthalmitis incidence, microbiological patterns, antibiotic resistance, and visual outcomes in a university hospital setting, with comparison to a private hospital cohort.
methodsThis retrospective cohort study analyzed 21,178 cataract surgeries performed at a university hospital (2014–2023). The incidence of endophthalmitis, microbiological profiles, resistance patterns, and visual acuity outcomes (LogMAR) were assessed. Intracameral moxifloxacin prophylaxis was introduced in 2019. A comparative analysis was conducted with 19,360 surgeries from a private hospital. Fisher’s exact test, Mann-Whitney U test, and Joinpoint regression were used for statistical analysis.
resultsEndophthalmitis incidence at the university hospital was 0.109% (23/21,178 surgeries), significantly higher than the 0.021% incidence in the private hospital (p = 0.002). Post-prophylaxis, infection rates declined from 0.219% in 2016 to 0.042% in 2023 (p = 0.003). Staphylococcus epidermidis predominated (52.6%), and moxifloxacin resistance remained stable (pre: 45.5%; post: no increase).
conclusionsIntracameral moxifloxacin significantly reduced endophthalmitis incidence without increasing bacterial resistance. Post-prophylaxis infection rates aligned with national surveillance benchmarks (e.g., SES-SP threshold of 0.07%), reinforcing the efficacy of this preventive strategy in a public university setting. The worsening of final visual acuity post-prophylaxis underscores the need for continued clinical vigilance. Ongoing microbiological surveillance remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.